In conclusion, anti-IL36R treatment is not only able to prevent the development of IL17A-driven psoriasis but also to inhibit and partially resolve psoriatic lesions and associated psoriasis-associated systemic inflammation. The gene discussed is IL17A; the disease is psoriasis.